A Phase II Trial of Cetuximab (C225) as Therapy for Recurrent Non-Small Cell Lung Cancer (NSCLC)
To determine the tumor response rate and time to disease progression, survival and safety in
the EGFR-positive, EGFR-negative and total populations.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary objective of this study was to determine the tumor response rate for single-agent cetuximab in EGFR+ subjects.
Every 8 weeks
E-mail: ClinicalTrials@ ImClone.com
United States: Food and Drug Administration
|ImClone Investigational Site||Indianapolis, Indiana 46202|
|ImClone Investigational Site||St. Charles, Missouri 63301|
|ImClone Investigational Site||Jacksonville, Florida 32207|
|ImClone Investigational Site||Decatur, Illinois 62526|
|ImClone Investigational Site||Boston, Massachusetts 02135|